Randomized, Open-Label, Phase 2 Study of Nivolumab Plus Ipilimumab or Nivolumab Monotherapy in Patients with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden. Michael Schenker , Mauricio Burotto , Martin Richardet , Tudor-Eliade Ciuleanu , Anthony Goncalves , Neeltje Steeghs , Patrick Schoffski , Paolo A. Ascierto , Michele Maio , Iwona Lugowska , Lorena Lupinacci , Alexandra Leary , Jean-Pierre Delord , Julieta Grasselli , David S. P. Tan , Jennifer Friedmann , Jacqueline Vuky , Marina Tschaika , Somasekhar Konduru , Sai Vikram Vemula , Ruta Slepetis , Georgia Kollia , Misena Pacius , Quyen Duong , Ning Huang , Parul Doshi , Jonathan Baden , Massimo Di Nicola Journal for ImmunoTherapy of Cancer（2024）
关键词
Combination therapy, Immune Checkpoint Inhibitor, Biomarker, Circulating tumor DNA - ctDNA, Tumor mutation burden - TMB
AI 理解论文
溯源树
样例
